Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather …
Endpoints News – Biotech and pharma business news, with a focus …
The FDA held 13 advisory committee panels last year to discuss specific product applications, half the total in 2023 and compared with nine in 2022.
Agenda: Endpoints at #JPM25 - events.endpts.com
Jan 13, 2025 · How a new Washington affects biopharma: In conversation with Scott Gottlieb . Investor, policy expert and former FDA Commissioner Scott Gottlieb will share his insights on …
Speakers: Endpoints at #JPM25 - events.endpts.com
Jan 13, 2025 · Managing Director, Global Head of Shareholder Activism & Corporate Defense. Morgan Stanley. Stephen J. Ubl
News – Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
Clinical Trials Day 2024
Dec 17, 2024 · Join Endpoints for a series of conversations on the latest trends in clinical trials in the US and abroad, the regulatory environment, and how expectations from the industry and …
Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on …
Nov 21, 2024 · Novartis is acquiring Kate Therapeutics for $1.1 billion, focusing on gene therapy and neuroscience. CEO Vas Narasimhan and CFO Harry Kirsch indicate future M&A deals will …
Special report 2024: Meet 20 women breaking new ground in …
Oct 7, 2024 · Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie …
Exclusive: Blood stem cell therapy maker Garuda gets new CEO, …
Nov 1, 2024 · Garuda Therapeutics has replaced its top leader and reeled in about $47 million to continue funding its blood stem cell therapy work, Endpoints News has learned. The …
Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive …
Nov 11, 2024 · US regulators gave the green light to Autolus Therapeutics’ cell therapy for adult B cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or …